Valuation: ARS Pharmaceuticals, Inc.

Market Cap 421M 376M 349M 318M 600M 40.71B 603M 4.21B 1.65B 20.76B 1.58B 1.55B 66.61B P/E 2026 *
-2.29x
P/E 2027 * -5.01x
Enterprise Value 421M 376M 349M 318M 600M 40.71B 603M 4.21B 1.65B 20.76B 1.58B 1.55B 66.61B EV / Sales 2026 *
3.24x
EV / Sales 2027 * 2.21x
Free-Float
83.82%
Yield 2026 *
-
Yield 2027 * -
1 day-7.24%
1 week+3.93%
Current month-1.86%
1 month-16.40%
3 months-46.73%
6 months-47.45%
Current year-63.69%
1 week 4.03
Extreme 4.03
4.64
1 month 3.98
Extreme 3.985
4.9
Current year 3.98
Extreme 3.985
13.15
1 year 3.98
Extreme 3.985
13.15
3 years 3.35
Extreme 3.35
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 05/08/2015
Chief Executive Officer 53 07/07/2026
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 A Free

Chief Executive Officer

1,036,923 1.0427%
9/1/26 A Free

Executive/Senior Manager

1,001,738 1.0073%
7/1/26 A Free

Chief Executive Officer

898,456 0.9048%
Change 5-day change 1-year change 3-year change Capi.($)
-7.24%+3.93%-62.63%+4.96% 421M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.02%-2.00%+38.39%+100.38% 37.7B
Weighted average by Cap. +0.55%-2.94%+51.22%+115.45%

Financials

2026 *2027 *
Net sales 130M 116M 108M 98.17M 185M 12.57B 186M 1.3B 509M 6.41B 488M 477M 20.57B 191M 170M 158M 144M 272M 18.45B 273M 1.91B 747M 9.41B 716M 700M 30.18B
Net income -184M -164M -153M -139M -263M -17.81B -264M -1.84B -721M -9.08B -691M -676M -29.14B -85.02M -75.93M -70.63M -64.25M -121M -8.23B -122M -850M -333M -4.19B -319M -312M -13.46B
Net Debt - -
Projected Income Statement - Annual - ARS Pharmaceuticals, Inc.
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
198
Date Price Change Volume
09/10/26 $4.230 -7.24% 1,258,395
08/10/26 $4.560 +4.59% 1,585,366
07/10/26 $4.360 +1.51% 1,297,976
06/10/26 $4.295 +0.12% 1,219,176
05/10/26 $4.290 +5.41% 1,621,610
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Ratings Surperformance© - ARS Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.230USD
Average target price
22.50USD
Spread / Average Target
+431.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ARS Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SPRY Stock